Cargando…

Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions

Cancer is the second leading cause of death worldwide. Specially, the high incidence rate and prevalence of drug resistance have rendered prostate cancer (PCa) a great threat to men’s health. Novel modalities with different structures or mechanisms are in urgent need to overcome these two challenges...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Qingmei, Zhou, Xin, Han, Fangxuan, Zheng, Caijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060886/
https://www.ncbi.nlm.nih.gov/pubmed/37007051
http://dx.doi.org/10.3389/fchem.2023.1137547
_version_ 1785017176526159872
author Ye, Qingmei
Zhou, Xin
Han, Fangxuan
Zheng, Caijuan
author_facet Ye, Qingmei
Zhou, Xin
Han, Fangxuan
Zheng, Caijuan
author_sort Ye, Qingmei
collection PubMed
description Cancer is the second leading cause of death worldwide. Specially, the high incidence rate and prevalence of drug resistance have rendered prostate cancer (PCa) a great threat to men’s health. Novel modalities with different structures or mechanisms are in urgent need to overcome these two challenges. Traditional Chinese medicine toad venom-derived agents (TVAs) have shown to possess versatile bioactivities in treating certain diseases including PCa. In this work, we attempted to have an overview of bufadienolides, the major bioactive components in TVAs, in the treatment of PCa in the past decade, including their derivatives developed by medicinal chemists to antagonize certain drawbacks of bufadienolides such as innate toxic effect to normal cells. Generally, bufadienolides can effectively induce apoptosis and suppress PCa cells in-vitro and in-vivo, majorly mediated by regulating certain microRNAs/long non-coding RNAs, or by modulating key pro-survival and pro-metastasis players in PCa. Importantly, critical obstacles and challenges using TVAs will be discussed and possible solutions and future perspectives will also be presented in this review. Further in-depth studies are clearly needed to decipher the mechanisms, e.g., targets and pathways, toxic effects and fully reveal their application. The information collected in this work may help evoke more effects in developing bufadienolides as therapeutic agents in PCa.
format Online
Article
Text
id pubmed-10060886
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100608862023-03-31 Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions Ye, Qingmei Zhou, Xin Han, Fangxuan Zheng, Caijuan Front Chem Chemistry Cancer is the second leading cause of death worldwide. Specially, the high incidence rate and prevalence of drug resistance have rendered prostate cancer (PCa) a great threat to men’s health. Novel modalities with different structures or mechanisms are in urgent need to overcome these two challenges. Traditional Chinese medicine toad venom-derived agents (TVAs) have shown to possess versatile bioactivities in treating certain diseases including PCa. In this work, we attempted to have an overview of bufadienolides, the major bioactive components in TVAs, in the treatment of PCa in the past decade, including their derivatives developed by medicinal chemists to antagonize certain drawbacks of bufadienolides such as innate toxic effect to normal cells. Generally, bufadienolides can effectively induce apoptosis and suppress PCa cells in-vitro and in-vivo, majorly mediated by regulating certain microRNAs/long non-coding RNAs, or by modulating key pro-survival and pro-metastasis players in PCa. Importantly, critical obstacles and challenges using TVAs will be discussed and possible solutions and future perspectives will also be presented in this review. Further in-depth studies are clearly needed to decipher the mechanisms, e.g., targets and pathways, toxic effects and fully reveal their application. The information collected in this work may help evoke more effects in developing bufadienolides as therapeutic agents in PCa. Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10060886/ /pubmed/37007051 http://dx.doi.org/10.3389/fchem.2023.1137547 Text en Copyright © 2023 Ye, Zhou, Han and Zheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Ye, Qingmei
Zhou, Xin
Han, Fangxuan
Zheng, Caijuan
Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions
title Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions
title_full Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions
title_fullStr Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions
title_full_unstemmed Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions
title_short Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions
title_sort toad venom-derived bufadienolides and their therapeutic application in prostate cancers: current status and future directions
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060886/
https://www.ncbi.nlm.nih.gov/pubmed/37007051
http://dx.doi.org/10.3389/fchem.2023.1137547
work_keys_str_mv AT yeqingmei toadvenomderivedbufadienolidesandtheirtherapeuticapplicationinprostatecancerscurrentstatusandfuturedirections
AT zhouxin toadvenomderivedbufadienolidesandtheirtherapeuticapplicationinprostatecancerscurrentstatusandfuturedirections
AT hanfangxuan toadvenomderivedbufadienolidesandtheirtherapeuticapplicationinprostatecancerscurrentstatusandfuturedirections
AT zhengcaijuan toadvenomderivedbufadienolidesandtheirtherapeuticapplicationinprostatecancerscurrentstatusandfuturedirections